标题
Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
作者
关键词
Ovarian cancer, Targeted therapies, Epithelial ovarian cancer, Molecular targets
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 2, Pages 221-234
出版商
Springer Nature
发表日期
2014-09-11
DOI
10.1007/s00280-014-2581-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review
- (2014) Nader Husseinzadeh et al. GYNECOLOGIC ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Antibody-based immunotherapy for ovarian cancer: where are we at?
- (2013) B. W. C. Tse et al. ANNALS OF ONCOLOGY
- Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications
- (2013) Ramez N. Eskander et al. GYNECOLOGIC ONCOLOGY
- Targeting Signaling Pathways in Epithelial Ovarian Cancer
- (2013) Elisabeth Smolle et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
- (2013) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study
- (2013) Paul Sabbatini et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
- (2012) Ting Gui et al. Cancer Epidemiology
- Role of Farletuzumab in Epithelial Ovarian Carcinoma
- (2012) Danijela Jelovac et al. CURRENT PHARMACEUTICAL DESIGN
- Hormone response in ovarian cancer: time to reconsider as a clinical target?
- (2012) Francesmary Modugno et al. ENDOCRINE-RELATED CANCER
- Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
- (2012) Ignacio Romero et al. ENDOCRINOLOGY
- Clinical trials and future potential of targeted therapy for ovarian cancer
- (2012) Hiroaki Itamochi et al. International Journal of Clinical Oncology
- American Society of Clinical Oncology 2012 Annual Meeting
- (2012) Krishnansu S. Tewari INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
- (2012) Patricia M. LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic strategies in epithelial ovarian cancer
- (2012) Ayako Kim et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on PARP1 inhibitors in ovarian cancer
- (2011) C. Sessa ANNALS OF ONCOLOGY
- PARP Inhibitor Treatment in Ovarian and Breast Cancer
- (2011) Marcie K. Weil et al. CURRENT PROBLEMS IN CANCER
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression
- (2011) Malti Kshirsagar et al. Journal of Oncology
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Met tyrosine kinase receptor in development and cancer
- (2008) Alessandra Gentile et al. CANCER AND METASTASIS REVIEWS
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
- (2008) Patricia Braly et al. JOURNAL OF IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started